XML 64 R54.htm IDEA: XBRL DOCUMENT
v3.23.2

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Dec. 31, 2021 | Jun. 30, 2020 | Jun. 30, 2023
Commitments And Contingencies [Line Items] |  |  |
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones |  |  | $ 765.5
Purchase commitment |  |  | 253.0
Purchase commitments expected to be paid in 2023 |  |  | 194.6
Early Stage Development Program | Third Party |  |  |
Commitments And Contingencies [Line Items] |  |  |
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones | $ 381.5 | $ 210.0 |
Shareholder vs BioMarin Pharmaceutical Inc |  |  |
Commitments And Contingencies [Line Items] |  |  |
Loss contingency |  |  | $ 39.0

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | bmrn_CommitmentsAndContingenciesLineItems
Namespace Prefix: | bmrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. + References No definition available. + Details
Name: | bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
Namespace Prefix: | bmrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + References No definition available. + Details
Name: | us-gaap_PurchaseObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. + References No definition available. + Details
Name: | us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bmrn_EarlyStageDevelopmentProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmrn_ThirdPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bmrn_ShareholderVsBioMarinPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |